IDEAYA Biosciences (NASDAQ:IDYA) Given New $35.00 Price Target at The Goldman Sachs Group

IDEAYA Biosciences (NASDAQ:IDYA) had its target price upped by The Goldman Sachs Group from $31.00 to $35.00 in a research report released on Tuesday,Benzinga reports. The firm currently has a neutral rating on the stock.

Other research analysts also recently issued reports about the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of IDEAYA Biosciences in a research note on Thursday, January 22nd. Wall Street Zen cut shares of IDEAYA Biosciences from a “buy” rating to a “sell” rating in a report on Saturday, February 21st. UBS Group started coverage on shares of IDEAYA Biosciences in a research report on Wednesday, January 7th. They issued a “buy” rating and a $50.00 price target on the stock. Truist Financial set a $65.00 price target on shares of IDEAYA Biosciences in a research report on Monday. Finally, Wells Fargo & Company raised their price target on shares of IDEAYA Biosciences from $44.00 to $48.00 and gave the stock an “overweight” rating in a research report on Tuesday. Fifteen research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $50.44.

IDEAYA Biosciences Price Performance

NASDAQ IDYA opened at $32.35 on Tuesday. IDEAYA Biosciences has a 12 month low of $15.84 and a 12 month high of $39.28. The company has a market capitalization of $2.84 billion, a price-to-earnings ratio of -24.69 and a beta of 0.02. The company’s fifty day moving average price is $32.38 and its two-hundred day moving average price is $32.62.

IDEAYA Biosciences (NASDAQ:IDYA) last posted its quarterly earnings data on Tuesday, February 17th. The company reported ($0.94) EPS for the quarter, beating analysts’ consensus estimates of ($1.03) by $0.09. The company had revenue of $10.88 million for the quarter, compared to the consensus estimate of $5.95 million. During the same quarter last year, the company earned ($1.49) earnings per share. The company’s revenue was up 55.7% compared to the same quarter last year. As a group, analysts anticipate that IDEAYA Biosciences will post -3.07 EPS for the current year.

Insider Activity

In other IDEAYA Biosciences news, Director Jeffrey Stein purchased 50,000 shares of IDEAYA Biosciences stock in a transaction dated Monday, March 2nd. The shares were bought at an average cost of $32.96 per share, for a total transaction of $1,648,000.00. Following the transaction, the director owned 54,281 shares in the company, valued at $1,789,101.76. This represents a 1,167.95% increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 2.50% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. Iron Triangle Partners LP bought a new position in shares of IDEAYA Biosciences in the 3rd quarter worth about $7,347,000. General American Investors Co. Inc. increased its holdings in shares of IDEAYA Biosciences by 7.7% in the 3rd quarter. General American Investors Co. Inc. now owns 280,261 shares of the company’s stock worth $7,626,000 after acquiring an additional 20,000 shares during the period. Candriam S.C.A. increased its holdings in shares of IDEAYA Biosciences by 10.8% in the 3rd quarter. Candriam S.C.A. now owns 1,012,967 shares of the company’s stock worth $27,563,000 after acquiring an additional 98,567 shares during the period. Cinctive Capital Management LP increased its holdings in shares of IDEAYA Biosciences by 193.9% in the 3rd quarter. Cinctive Capital Management LP now owns 49,946 shares of the company’s stock worth $1,359,000 after acquiring an additional 32,953 shares during the period. Finally, Knights of Columbus Asset Advisors LLC acquired a new stake in shares of IDEAYA Biosciences in the 3rd quarter worth about $934,000. 98.29% of the stock is currently owned by institutional investors.

IDEAYA Biosciences News Summary

Here are the key news stories impacting IDEAYA Biosciences this week:

• Positive Sentiment: Positive topline registrational data from the OptimUM-02 Phase 2/3 trial: darovasertib + crizotinib improved median PFS to 6.9 months vs. 3.1 months for control (HR 0.42; 95% CI: 0.30–0.59), meeting the primary endpoint — a result that supports regulatory and commercial upside in metastatic uveal melanoma. PR Newswire
• Positive Sentiment: Market reaction/press coverage pushed the stock sharply higher overnight and in early trading as outlets reported the trial success, creating momentum and heightened investor attention. Investing.com article
• Positive Sentiment: Several firms raised price targets and issued bullish ratings after the data — notable raises include Wedbush to $58 (Outperform), Wells Fargo to $48 (Overweight) and Guggenheim to $54 (Buy) — signaling significant analyst upside expectations. Benzinga The Fly
• Neutral Sentiment: Goldman Sachs raised its price target to $35 but kept a “Neutral” rating — a reminder that not all sell-side desks expect an immediate re-rating into the highest target bands. Benzinga
• Negative Sentiment: Analyst/media caveats and regulatory risk remain — some commentary notes that approval and commercialization are not automatic despite strong PFS, so development and labeling/regulatory paths still carry execution risk. Seeking Alpha
• Negative Sentiment: Profit‑taking and volatility after the sizable overnight rally are likely driving the intraday pullback despite the positive fundamentals — volume is elevated and short-term traders may be locking gains.

About IDEAYA Biosciences

IDEAYA Biosciences is a clinical-stage precision oncology company dedicated to the discovery and development of novel therapies that exploit synthetic lethality in cancer cells. By targeting key DNA damage response pathways, the company aims to selectively kill tumor cells exhibiting specific genetic vulnerabilities while sparing healthy tissue. IDEAYA’s pipeline includes small-molecule inhibitors designed to address underserved tumor types, and its lead programs are advancing through Phase 1 and Phase 2 clinical trials in multiple oncology indications.

Central to IDEAYA’s approach is its Modular Approach to Precision (MAP) platform, which integrates proprietary genomic and functional screening technologies to identify critical cancer-specific dependencies.